Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmacosmo SpA's Ending Cash Position for the quarter that ended in Dec. 2025 was €0.95 Mil.
Farmacosmo SpA's quarterly Ending Cash Position
declined
from Dec. 2024 (€3.12 Mil) to Jun. 2025 (€2.01 Mil) and
declined
from Jun. 2025 (€2.01 Mil) to Dec. 2025 (€0.95 Mil).
Farmacosmo SpA's annual Ending Cash Position
declined
from Dec. 2023 (€5.07 Mil) to Dec. 2024 (€3.12 Mil) and
declined
from Dec. 2024 (€3.12 Mil) to Dec. 2025 (€0.95 Mil).
Farmacosmo SpA Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Farmacosmo SpA's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Farmacosmo SpA's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of €0.95 Mil mean?
Farmacosmo SpA (MIL:COSMO) has a Ending Cash Position of €0.95 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Farmacosmo SpA and its competitors.
Is Farmacosmo SpA's Ending Cash Position too high?
Farmacosmo SpA's current Ending Cash Position is €0.95 Mil. Overall, Farmacosmo SpA has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Farmacosmo SpA's Ending Cash Position compare to competitors?
Farmacosmo SpA's Ending Cash Position of €0.95 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Farmacosmo SpA and its competitors. Farmacosmo SpA's current Ending Cash Position is €0.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmacosmo SpA stock overvalued right now?
Based on GuruFocus' analysis, Farmacosmo SpA (MIL:COSMO) is currently considered Possible Value Trap. The stock's GF Value™ is €0.76, compared to a current price of €0.47 — trading 38% below its estimated fair value. The current Ending Cash Position is €0.95 Mil. Farmacosmo SpA's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Farmacosmo SpA (MIL:COSMO), the current Ending Cash Position is €0.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmacosmo SpA (MIL:COSMO) Overvalued in 2026?
Based on GuruFocus' analysis, Farmacosmo SpA stock appears to be undervalued.
The current stock price of €0.47 is trading 38% below its estimated GF Value™ of €0.76.
GuruFocus considers Farmacosmo SpA to be Possible Value Trap.
Key valuation signals for MIL:COSMO:
Ending Cash Position: €0.95 Mil
GF Value™: €0.76 vs. price of €0.47 (38% below fair value)
No single metric tells the full story. See the MIL:COSMO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmacosmo SpA is a wellness e-commerce company active in the Health, Pharma, and Wellness industry, authorized by the Italian Ministry of Health to sell pharmaceutical products online. In particular, the company offers parapharmaceutical products, vitamins and food supplements, dietetic products, medical devices, cosmetic products, personal hygiene products, hair care products, dental care products, skincare products, perfumes, home and baby items.
34GF Score
Get the complete analysis for MIL:COSMO
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:COSMO has been successfully added to your 
